22 related articles for article (PubMed ID: 8840306)
1. The effects of calcitriol with calcium carbonate supplementation on inflammatory biomarkers in chronic kidney disease patients' with low vitamin D.
Mustafar RB; Mohd R; Miswan NA; Bain A; Cader R; Gafor AH; Mohammad M; Shah SA; Kamaruddin NA; Kong NC
Cent Eur J Immunol; 2014; 39(2):236-42. PubMed ID: 26155130
[TBL] [Abstract][Full Text] [Related]
2. The role of 25-hydroxyvitamin D deficiency in promoting insulin resistance and inflammation in patients with chronic kidney disease: a randomised controlled trial.
Petchey WG; Hickman IJ; Duncan E; Prins JB; Hawley CM; Johnson DW; Barraclough K; Isbel NM
BMC Nephrol; 2009 Dec; 10():41. PubMed ID: 20003316
[TBL] [Abstract][Full Text] [Related]
3. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D therapy modulates cytokine secretion in patients with renal failure.
Riancho JA; Zarrabeitia MT; de Francisco AL; Amado JA; Napal J; Arias M; Gonzalez-Macias J
Nephron; 1993; 65(3):364-8. PubMed ID: 8289985
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels.
Borazan A; Ustün H; Cefle A; Sekitmez N; Yilmaz A
J Int Med Res; 2003; 31(6):489-96. PubMed ID: 14708413
[TBL] [Abstract][Full Text] [Related]
6. The effects of calcitriol therapy on serum interleukin-1, interleukin-6 and tumour necrosis factor-alpha concentrations in post-menopausal patients with osteoporosis.
Inanir A; Ozoran K; Tutkak H; Mermerci B
J Int Med Res; 2004; 32(6):570-82. PubMed ID: 15587751
[TBL] [Abstract][Full Text] [Related]
7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
8. Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
Inaba M; Okuno S; Nagayama H; Yamada S; Ishimura E; Imanishi Y; Shoji S
J Ren Nutr; 2015 Mar; 25(2):242-6. PubMed ID: 25556148
[TBL] [Abstract][Full Text] [Related]
9. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
Coburn JW; Elangovan L
J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
[TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of calcitriol and calcium carbonate on secretion of interleukin-1 beta and tumour necrosis factor-alpha by uraemic peripheral blood mononuclear cells.
Tsukamoto Y; Nagaba Y; Izumida I; Morishita T; Saitoh M
Nephrol Dial Transplant; 1996; 11 Suppl 3():15-21. PubMed ID: 8840306
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
